The U.S. National Institute of Allergy and Infectious Diseases (NIAID) has funded a new study led by researchers at the Albert Einstein College of Medicine in New York with $603,661.
Launched on June 1, 2024, the goal of this follow-up project (PA-20-185) is to accelerate the development of strategies to bolster vaccine and monoclonal antibody (mAb) efficacy against a range of pathogens such as herpes simplex virus (HSV).
The total project funding amount for the two projects is now $1,231,761.
Read More
